CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the ...

As with other drugs, Eliquis (apixaban) can cause side effects, such as anemia and minor bleeding. If you are not able to tolerate side effects of Eliquis, talk with your doctor or pharmacist.

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Patients were randomized in a double-blind fashion to receive 2.5 mg or 5 mg apixaban (Eliquis; Bristol Myers Squibb) twice daily for 12 months. The median time between the index VTE and enrollment ...

For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants (OACs) may carry a higher bleeding risk than others, according to a study based on Medicare records.

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).